Ciclosporin - Nanomerics

Drug Profile

Ciclosporin - Nanomerics

Alternative Names: Cyclosporine A - Nanomerics; METSporine; NM 133; NM-0133

Latest Information Update: 13 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nanomerics
  • Class Antineoplastics; Antipsoriatics; Antirheumatics; Ciclosporins; Eye disorder therapies; Neuroprotectants
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Dry eyes

Most Recent Events

  • 10 Jan 2017 Ciclosporin licensed to IACTA Pharmaceuticals in North America
  • 10 Aug 2016 Chemical structure information added
  • 28 Jul 2016 Phase-I clinical trials in Dry eyes in United Kingdom (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top